WO2006022314A1 - Contrôleur du métabolisme du cholestérol et aliments, boissons, additifs alimentaires et médicaments contenant celui-ci - Google Patents

Contrôleur du métabolisme du cholestérol et aliments, boissons, additifs alimentaires et médicaments contenant celui-ci Download PDF

Info

Publication number
WO2006022314A1
WO2006022314A1 PCT/JP2005/015394 JP2005015394W WO2006022314A1 WO 2006022314 A1 WO2006022314 A1 WO 2006022314A1 JP 2005015394 W JP2005015394 W JP 2005015394W WO 2006022314 A1 WO2006022314 A1 WO 2006022314A1
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol
extract
cholesterol metabolism
hop
polyphenol
Prior art date
Application number
PCT/JP2005/015394
Other languages
English (en)
Japanese (ja)
Inventor
Yoko Akazome
Toshiaki Waga
Tomomasa Kanda
Manabu Sami
Yutaka Ohta
Masaaki Yasue
Original Assignee
Asahi Breweries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Breweries, Ltd. filed Critical Asahi Breweries, Ltd.
Publication of WO2006022314A1 publication Critical patent/WO2006022314A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Cholesterol metabolism regulator food and drink containing the same, food additive and medical technology
  • the present invention relates to a cholesterol metabolism regulator obtained from apples or hop koji, a food or drink containing the same, a food additive, and a medicine.
  • Arteriosclerosis is a force known to develop and develop due to the overlap of various factors. Among them, the most important factor is considered to be hyperlipidemia, especially hypercholesterolemia. So far, the most emphasis has been on countermeasures.
  • Non-patent Document 1 Today, hypercholesterolemia is a time when more effective treatment should be performed to prevent arteriosclerosis rather than uniform treatment.
  • cholesterol which is a kind of lipid component widely present in the animal kingdom, is a component of biological membranes of cells and tissues, and before bile, sex hormones, corticosteroids, vitamin D, etc. Although it is a useful substance that serves as a precursor, it is particularly abundant in egg meat and tends to be consumed in excess of the changes in dietary habits in recent years.
  • HDL high density lipoprotein
  • LDL-cholesterol acts antagonistically with LDL-cholesterol. That is, it is known to have an action of removing free cholesterol excessively accumulated in arterial walls and peripheral tissues and reducing a body's cholesterol pool, that is, an action of promoting lipid excretion.
  • lipid metabolism control agents pravastatin sodium and bezafibrate are known for pharmaceuticals, and dietary fiber, polyphenol and the like are known for food-derived ingredients.
  • Patent Document 2 reports a cholesterol metabolism improving agent for salmon tannin.
  • the cholesterol metabolism control action by the high molecular weight condensed polyphenolic compound is only described, and the cholesterol metabolism controlling action of the low molecular weight condensed polyphenolic compound is only described. Is not mentioned at all.
  • Patent Document 1 Japanese Patent Laid-Open No. 10-330278
  • Patent Document 2 Japanese Patent Laid-Open No. 2003-231684
  • Non-patent document 1 Guidelines for the treatment of arteriosclerotic diseases, Japan Atherosclerosis Society, 2002 Disclosure of the invention
  • the problem to be solved by the present invention is a food and drink that has an effect of reducing cholesterol absorption, has a cholesterol-reducing action that is derived from a natural substance that has a normal diet and has no dietary restrictions, and has high safety. It is to provide food additives or medicines.
  • hop koji extract or hop koji is a polyphenol-like substance contained in hop koji extract or hop koji, adsorbed on gel-type synthetic resin, and does not pass through the membrane when treated with an ultrafiltration membrane with a molecular weight cut off of 1,000 or more.
  • the substance, that is, hop koji is extracted with water or an aqueous solution of an organic solvent miscible with water, treated with a gel-type synthetic resin or ultrafiltration membrane, and the fractions obtained through each treatment step are cholesterol-controlling effects. It was found to have
  • the gist of the present invention is as follows.
  • a cholesterol metabolism regulator comprising an apple extract or a hop koji extract as an active ingredient.
  • a cholesterol metabolism regulator which is a hop koji extract and a substance adsorbed on an adsorption resin that adsorbs a polyphenol-like substance.
  • a cholesterol metabolism regulator which is a hop koji extract and is a substance that does not permeate the membrane when treated with an ultrafiltration membrane having a molecular weight cut off of 1,000 or more.
  • a cholesterol metabolism control agent that is a polyphenol-like substance contained in hop koji and is a substance that does not permeate the membrane when treated with an ultrafiltration membrane having a molecular weight cut off of 1,000 or more.
  • a food additive comprising the cholesterol metabolism regulator according to any one of (1) to (4).
  • a medicament comprising the cholesterol metabolism regulator according to any one of (1) to (4).
  • the cholesterol metabolism control agent comprising the apple extract or hop koji extract of the present invention as an active ingredient can control cholesterol metabolism with very few side effects.
  • FIG. 1 is a graph showing serum and liver cholesterol concentrations in rats fed with apple-derived polyphenol.
  • FIG. 2 is a graph showing the serum cholesterol concentration of rats fed polyphenol derived from hop koji.
  • the apple extract in the cholesterol metabolism regulator of the present invention contains apple-derived polyphenol as an active ingredient.
  • the cholesterol metabolism control agent containing the apple extract of the present invention as an active ingredient is a low molecular procyanidin that is absorbed into the body to reduce the expression of the cholesterol metabolism gene in the liver. It is speculated that higher molecular procyanidins inhibit and promote cholesterol metabolism by synergistic effects of inhibiting absorption and excretion of cholesterol and bile acids.
  • the procyanidins in the apple extract of the present invention are specifically a collective term for procyanin gin Bl, procyanin gin B2, procyanin gin C1 and the like in which catechin is polycondensed.
  • the apple extract containing apple polyphenol used in the present invention is extracted from fruits of the genus Rosaceae, for example, cultivars such as Fuji, Mutsu, Tsugaru, Starking Delicious, and original apples. Obtained.
  • the fruit both a mature fruit and an immature fruit can be used. However, since the fruit contains more polyphenol compounds and contains a large amount of various active ingredients having a wide range of physiological effects, Particularly preferred.
  • the apple polyphenol contained in the apple extract of the present invention is an apple fruit or juice juice of immature fruit, or a polyphenol fraction purified from the extract.
  • the minute fraction is purified by treating the juice and extract with an adsorbent, and the fraction adsorbed on the adsorbent (hereinafter referred to as the adsorbed fraction) contains polyphenol.
  • the polyphenol fraction is purified.
  • the polyphenol fraction can then be concentrated to obtain a liquid formulation, and further, a powder formulation can be obtained by spray drying or freeze-drying the liquid formulation.
  • procyan-azines are mostly present as dimers and trimers. High-molecular procyanidins are denatured or acidified by heating or treatment with alkali or the like. ⁇ ⁇ ⁇ Easy to disassemble.
  • the washed raw material is adjusted to pH 3.2 to 4.6, preferably pH 3.
  • pectinase is clarified at 5 to 75 ° C, preferably 30 to 60 ° C at 10 to: LOOppm, preferably 20 to 30ppm, and centrifuged. 5 ⁇ 75 ° C Further, clarification is preferably performed by filtration through diatomaceous earth (trade name “Silica 300S”, manufactured by Chuo Silica Co., Ltd.) at 15 to 25 ° C. Alternatively, partitioning and filtration with an organic solvent such as hexane or chloroform is performed to obtain a clarified extract.
  • diatomaceous earth trade name “Silica 300S”, manufactured by Chuo Silica Co., Ltd.
  • the clarified fruit juice is adsorbed at 0 to 40 ° C, preferably 15 to 25 ° C, pH 1 to 5 to 4.2, preferably pH 3.0 to 4.0 (trade name “SEPA BEEDS SP-850”, Mitsubishi To make the polyphenols adsorbed.
  • pure water is passed through to remove non-adsorbing substances (sugars, organic acids, etc.) in the column, and then elution is performed with 10 to 90%, preferably 30 to 80% ethanol. Extract ethanol from the obtained fraction under reduced pressure at 25 to 100 ° C, preferably 35 to 90 ° C, extract the concentrate as it is or add a powder auxiliary such as dextrin, perform spray drying or freeze drying, and extract A powder product is obtained.
  • the content of procyanidins in the total polyphenol in the preparation is preferably 20 to 100% by weight, more preferably 30 to 90% by weight, and particularly preferably 40 to 65% by weight. Furthermore, the proportion of the dimer and trimer in procyanin is preferably 20 to 80% by weight, more preferably 25 to 70% by weight, and particularly preferably 30 to 70% by weight. Within this range, effects such as serum and / or liver total cholesterol reduction, LDL-cholesterol reduction, HDL-cholesterol elevation, and expression of liver cholesterol regulatory genes are clearly expressed.
  • the content of procyanidins is 10 to 80% by weight, preferably 15 to 70% by weight, the dimer and the Z or trimer strength are selected, the taste as a preparation Is more preferable and can be used continuously without difficulty.
  • the daily dose is 100 to 2500 as a procedureazine.
  • the hop koji extract in the cholesterol metabolism control agent of the present invention contains hop koji-derived polyphenol as an active ingredient.
  • the hop koji extract containing hop koji polyphenol used in the present invention is obtained by removing the rubulin part from the hop koji, and in general, the hop koji is pulverized and then sieved. Get the Hop Hope by removing.
  • the hop fruit is directly formed into pellets without removing hop cake that is not useful for beer brewing, It tends to be used for brewing. Therefore, the raw material of the present invention is not particularly limited as long as it contains hop cake, and there is no problem even if hop fruit and hop pellets containing hop cake are used as raw materials.
  • the extraction method of the hop koji extract is not particularly limited.
  • the hop koji or hop pellet containing the hop koji or hop koji as a raw material is preferably 4 to 95 ° C, preferably Extract at 30-60 ° C with 0-50%, preferably 10-40% ethanol.
  • the ratio of the raw material to the extraction solvent is 1:20 to 100 (weight ratio), preferably 1:30 to 90 (weight ratio), and is carried out with stirring for 20 to 60 minutes, preferably 30 to 50 minutes. Further clarification is performed by filtration through diatomaceous earth (trade name “Silica 300S”, manufactured by Chuo Silica Co., Ltd.) at 5 to 75 ° C., preferably 15 to 25 ° C. Since hop koji extract has a cholesterol metabolism control action, it is useful as a cholesterol metabolism control agent.
  • the polyphenol-like substance contained in the hop koji extract has a cholesterol metabolism control action, it is useful as a cholesterol metabolism control agent.
  • the hop koji extract is adsorbed with an adsorption resin that adsorbs the polyphenol-like substance, and the hop koji extract liquid power hop koji-derived polyphenol-like substance is used. May be separated and purified.
  • the adsorption treatment method is not particularly limited.
  • the hop koji extract may be adsorbed on the adsorption resin at 0 to 40 ° C, preferably 15 to 25 ° C.
  • the adsorbed resin is not particularly limited as long as it adsorbs a polyphenol-like substance.
  • hydrophilic bur polymer resin (“Toyopearl HW40” manufactured by Toso Co., Ltd.), styrene-di-vinylbenzene resin (Mitsubishi) "Separbeads SP-825" manufactured by Eigakusha), gel-type synthetic resin (Mitsubishi “Diaion HP-20” manufactured by Kagaku Co., Ltd.).
  • the hop koji extract is passed through an adsorption column packed with these adsorbents to adsorb polyphenol-like substances.
  • pure water is passed through to remove non-adsorbed substances (saccharides, organic acids, etc.) in the column, and then the polyphenol-like substance is eluted with 10 to 90%, preferably 30 to 80% ethanol. Good.
  • hop koji extract or hop koji a substance that does not permeate the membrane when treated with an ultrafiltration membrane with a molecular weight cut off of 1,000 or more is cholesterol in the small intestine. This is preferable in that it inhibits micelle solubility and controls entry into the living body.
  • the treatment liquid containing the hop koji extract or the hop koji-derived polyphenol-like substance obtained in the above extraction step or adsorption step has a molecular weight cutoff of 1,000 or more, preferably 10,000 to 50,000. Treat with filtration membrane. At that time, if necessary, the treatment liquid containing the hop koji-derived polyphenol-like substance can be concentrated under reduced pressure to lower the ethanol concentration. Depending on the concentration of the organic solvent in the extraction solvent and the ratio of the extraction solvent and hops or hops, the treatment is carried out until the amount of the remaining liquid is approximately iZio to iZioo, preferably 1Z20 to 1Z100 at the start of the treatment. .
  • the pressure at that time is 9.8 kPa to 981 kPa, preferably 98 kPa to 686 kPa. It can be used in the liquid state as it is, but it can also be dried as described below.
  • the obtained fractional force is also concentrated under reduced pressure at 25 to 100 ° C, preferably 35 to 90 ° C, and spray-dried or lyophilized with the concentrated solution as it is or with the addition of a powder auxiliary such as dextrin. Get the extracted powder product.
  • the method for obtaining a hop koji-derived polyphenol-like substance that does not pass through the membrane when treated with an ultrafiltration membrane having a molecular weight cut off of 1,000 or more is limited to the above method.
  • the treatment liquid that does not permeate the ultrafiltration membrane may be adsorbed with a gel polymer.
  • the daily dose of hop koji extract for obtaining an effect of reducing serum total cholesterol, LDL-cholesterol, and HDL-cholesterol by hop koji extract is as follows: 200-5000 mg, preferably 30 0-3000 mg, more preferably 300-2000 mg, particularly 300-1500 mg.
  • the cholesterol metabolism control agent of the present invention can be used as a food additive by adding it to a wide variety of foods, including beverages.
  • beverages for example, soups, beverages (juice, liquor, mineral water, coffee, tea Etc.), confectionery (gum, candy, chocolate, snack, jelly, etc.), and rice cake (soba, udon, ramen, etc.).
  • Prussia contained in apple extract in beverages - content of oxazines is 0.05 to 1.25 weight 0/0, preferably 0.15 to 0.75% by weight, particularly 0.3 to 0.5% by weight is preferred. This amount is preferable because it allows easy intake of large amounts of procazines, but does not cause bitterness. If it is 0.05% by weight or more, it is preferable because it has a rich taste when taken.
  • the content of the hop koji-derived extract in the beverage is 0.1 to 2.5 wt%, preferably 0.3 to 1.5 wt%, particularly 0.6. ⁇ 1% by weight is preferred. This amount makes it easy to ingest large amounts of hop koji extract
  • the food containing the cholesterol metabolism regulator of the present invention can be used for food containing cholesterol as part of the food.
  • strong cholesterol-containing foods include health foods that exhibit specific functions to promote health. Specific examples include mayonnaises, liver pastes, custard creams and cakes containing strong cholesterol.
  • Formulations of cholesterol metabolism controlling agents containing apple extract, in the formulation, Prussia two oxazines is 0.05 to 1.25 weight 0/0, preferably from 0.15 to 0.75 weight 0/0, further 0.3 to 0.5 wt 0 It is preferable to contain / 0 . This amount is preferable in view of the number of administrations and effects because it is easy to take a large amount without the bitter taste of procyanin.
  • the hop koji extract contains 0.1 to 2.5% by weight, preferably 0.3 to 1.5% by weight, and further 0.6 to 1% by weight. Is preferred. This amount makes it easy to ingest large amounts without the bitter taste of hop koji extract It is preferable in terms of the number of administrations and effects.
  • the pharmaceutical dosage form containing the cholesterol metabolism control agent of the present invention is not particularly limited, but for example, solid preparations such as tablets, powders, fine granules, granules, capsules, pills, liquid preparations, suspensions, etc.
  • Orally administered agents such as syrups and liquids such as emulsions.
  • This orally administered agent includes excipients, disintegrants, binders, lubricants, surfactants, alcohols, water, water-soluble polymers, sweeteners, and flavoring agents that are usually used in the art depending on the form. Further, it can be produced by a commonly used method by adding a sour agent, a carrier for medicine, and the like.
  • the procyanidins are generally contained in an orally-administered drug in an amount of 0.1 to 100% by weight, particularly 1 to 80% by weight, although it varies depending on the use and form of the drug.
  • the hop koji extract is preferably contained in an orally-administered drug in an amount of 0.2 to 100% by weight, particularly 2 to 80% by weight, which varies depending on the use and form of the drug.
  • Mobile phase A solution is 10% methanol aqueous solution containing 10 mmol / L potassium phosphate
  • solution B is 10% methanol aqueous solution containing 10 mmol / L potassium phosphate
  • sample injection volume is 20 L
  • UV detector wavelength is 280
  • Feed composition (% by weight)
  • Corn starch 36.4986 (including apple polyphenol)
  • Vitamin 2 1% by weight
  • Vitamin Mixture AIN93 (made by Oriental Yeast Co., Ltd.)
  • RNAlater Tropa Bio Inc.
  • RNA was purified using RNeasy (manufactured by Qiagen). From the total RNA obtained, ABI PRISM High Capacity cDNA Archive Kit (Applied Biosystems Japan Co., Ltd.) CDNA synthesis was carried out. Obtained cDNA is SYBR
  • DHCR7 reductase
  • polypeptide 1 (CYP7Al) mRNA is shown in Table 1.
  • Tablet test subjects (control group (Comparative Example 1, apple-derived polyphenol 0) to 48 test subjects (men and women aged 20 to 65 years) in the borderline whose serum total cholesterol is 200 to 260 mg / dL 0 mg: 12 persons), low-dose group (Example, Apple-derived polyphenol 300 mg: 12 persons), medium-dose group (Example)
  • Apple-derived polyphenol 600 mg 12 persons
  • high-dose group Example 3
  • apple-derived polyphenol
  • the dose was mg / kg for 14 days with a stomach tube. No abnormalities were observed in the general condition and body weight during the experiment, and no abnormalities were observed in the general blood tests and anatomical findings after the experiment.
  • the dose was mg / kg for 90 days with a gastric sonde. No abnormalities were observed in the general condition and body weight at the time of the experiment, and the general blood test and anatomical findings after the experiment were also strong.
  • the dose was mg / kg by gastric sonde.
  • General condition no abnormality in weight, no micronucleus There was no significant difference in the appearance of polychromatic erythrocytes and polychromatic erythrocytes compared to the negative control group.
  • hop blossoms 20 g were pulverized in a mortar and extracted with 2 L of water at 95 ° C. for 40 minutes while stirring. After filtration, the mixture was allowed to cool, and the extract was treated with an ultrafiltration membrane having a molecular weight cut off of 50,000 (XM50 manufactured by Amicon Co., Ltd.) at 98 kPa at room temperature to 20 mL. The obtained remaining liquid was dried under reduced pressure to obtain 0.2 g of a pale yellow powder having an odorless faint bitterness. The yield from hop camellia was 1%.
  • hop koji 20 g was extracted with 600 mL of a 50% aqueous ethanol solution at 80 ° C. for 40 minutes while stirring. After filtration, the extract is applied to an ultrafiltration membrane (Amicon YM10) with a molecular weight cut-off of 10,000. Then, the mixture was treated at 294 kPa at room temperature until it reached 60 mL. The obtained remaining liquid was freeze-dried to obtain 0.8 g of a pale yellow powder having a faint bitter taste with no odor. The yield from hop cake was 4%.
  • Feed composition (% by weight)
  • Pulp extract was administered at a dose of 2000 3000 mg / kg for 14 days with a gastric sonde. No abnormalities were observed in the general condition and weight during the experiment, and no abnormalities were observed in the general blood tests and anatomical findings after the experiment. [0094] ⁇ 28-day repeated dose toxicity study)
  • the male and female SD rats (Japanese chili survivor) were divided into 6 each, and the hop cocoon extract prepared in Production Example 4 was 500, 1000, 2000.
  • the dose was mg / kg for 28 days using a stomach tube. No abnormalities were observed in the general condition and body weight during the experiment, and no abnormalities were observed in the general blood tests and anatomical findings after the experiment.
  • the dose was mg / kg by gastric sonde. There was no abnormality in general condition and body weight, and there was no significant difference in the appearance frequency of polychromatic erythrocytes with micronuclei and polychromatic erythrocytes compared to the negative control group. there were.
  • a cholesterol metabolism regulator comprising an apple extract or hop koji extract as an active ingredient is useful because it has very few side effects and can control cholesterol metabolism.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

[PROBLÈMES]Cette invention concerne un contrôleur du métabolisme du cholestérol provenant d’un matériau naturel et ayant un effet de contrôle du métabolisme du cholestérol avec peu de risques d’effets secondaires. [MOYENS POUR RÉSOUDRES CES PROBLÈMES] Ce contrôleur du métabolisme du cholestérol est un extrait de pomme et contient des polyphénols, provenant de pommes, en tant qu’ingrédient actif.
PCT/JP2005/015394 2004-08-25 2005-08-25 Contrôleur du métabolisme du cholestérol et aliments, boissons, additifs alimentaires et médicaments contenant celui-ci WO2006022314A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004-244847 2004-08-25
JP2004244847 2004-08-25
JP2004271544 2004-09-17
JP2004-271544 2004-09-17

Publications (1)

Publication Number Publication Date
WO2006022314A1 true WO2006022314A1 (fr) 2006-03-02

Family

ID=35967521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/015394 WO2006022314A1 (fr) 2004-08-25 2005-08-25 Contrôleur du métabolisme du cholestérol et aliments, boissons, additifs alimentaires et médicaments contenant celui-ci

Country Status (1)

Country Link
WO (1) WO2006022314A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60156614A (ja) * 1984-01-26 1985-08-16 Mitsui Norin Kk コレステロ−ル上昇抑制剤
JPH01299224A (ja) * 1988-05-24 1989-12-04 Itouen:Kk コレステロール排泄促進剤及びコレステロール排泄促進飲食物
JPH09291039A (ja) * 1995-12-26 1997-11-11 Suntory Ltd プロシアニジンを有効成分とする抗肥満剤
JPH10330278A (ja) * 1997-05-27 1998-12-15 Nikka Uisukii Kk 果実ポリフェノールを有効成分とする生体内脂質代謝制御剤
JP2001131080A (ja) * 1999-11-02 2001-05-15 Asahi Breweries Ltd ホップより得られる体重増加抑制物質
JP2001321166A (ja) * 2000-05-17 2001-11-20 Asahi Breweries Ltd ホップより得られるリパーゼ阻害物質
JP2004256481A (ja) * 2003-02-27 2004-09-16 Asahi Breweries Ltd ポリフェノールの分離方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60156614A (ja) * 1984-01-26 1985-08-16 Mitsui Norin Kk コレステロ−ル上昇抑制剤
JPH01299224A (ja) * 1988-05-24 1989-12-04 Itouen:Kk コレステロール排泄促進剤及びコレステロール排泄促進飲食物
JPH09291039A (ja) * 1995-12-26 1997-11-11 Suntory Ltd プロシアニジンを有効成分とする抗肥満剤
JPH10330278A (ja) * 1997-05-27 1998-12-15 Nikka Uisukii Kk 果実ポリフェノールを有効成分とする生体内脂質代謝制御剤
JP2001131080A (ja) * 1999-11-02 2001-05-15 Asahi Breweries Ltd ホップより得られる体重増加抑制物質
JP2001321166A (ja) * 2000-05-17 2001-11-20 Asahi Breweries Ltd ホップより得られるリパーゼ阻害物質
JP2004256481A (ja) * 2003-02-27 2004-09-16 Asahi Breweries Ltd ポリフェノールの分離方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] STEVENS ET AL: "Identification and in Vitro Biological Activities of Hop Proanthocyanidins: Inhibition of nNOS Activity and Scavenging of ReactiveNitrogen Species.", XP002993285, Database accession no. (2002:340178) *
J AGRIC FOOD CHEMISTRY, vol. 50, no. 12, 2002, pages 3435 - 3443 *

Similar Documents

Publication Publication Date Title
KR100473919B1 (ko) 저 밀도 지단백질 콜레스테롤 농도를 저하시키기 위한 조성물
JP4669920B2 (ja) 血糖上昇抑制且つ血圧上昇抑制作用を有する機能性素材
EP2799083A1 (fr) Agent de prévention de l'atrophie musculaire
US20080293644A1 (en) Guava extract
JP2008297209A (ja) 脂質代謝改善組成物
JP4686173B2 (ja) ポリフェノールおよび／またはビタミンｃを含有するアセロラ処理物
JP2011190245A (ja) 明日葉のカルコン及びイソフラボンを含有する組成物
JP2001131080A (ja) ホップより得られる体重増加抑制物質
JP2006193502A (ja) アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬
JP2009298769A (ja) 脂肪蓄積抑制用組成物
JP6042800B2 (ja) トマトシドａの抽出方法
JP2010095478A (ja) 体脂肪蓄積抑制剤及び飲食品
JP2008044872A (ja) イソラリシレシノールを含有する健康食品、血中コレステロール降下剤および体脂肪低下剤
KR101820096B1 (ko) 콩 발아배아 추출물을 포함하는 대사성 질환의 예방 또는 치료용 약학 조성물
JP4673071B2 (ja) 鉄吸着性高分子物質及び鉄含有高分子物質ならびにこれらの製造方法
KR102239066B1 (ko) 식물 추출물의 혼합물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물
EP1679079A1 (fr) Composition d'extrait de graines vegetales et procede pour la produire
KR101910099B1 (ko) 미성숙 감으로부터 가압 열수 방법으로 추출한 추출물 유효성분으로 포함하는 지질대사 개선 또는 항비만용 조성물
JP2006193501A (ja) アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬
WO2006046402A1 (fr) Agent de controle du metabolisme des triglycerides et aliments, boissons, additifs alimentaires et produits pharmaceutiques le contenant
JP2006151945A (ja) 中性脂肪低減剤、それを含有する飲食品、食品添加物及び医薬
WO2006064761A1 (fr) Agent régulateur d'adiponectine et aliments, boissons, additifs alimentaires et médicaments incluant ledit agent
WO2006022314A1 (fr) Contrôleur du métabolisme du cholestérol et aliments, boissons, additifs alimentaires et médicaments contenant celui-ci
KR20080035853A (ko) 미나리 추출물을 유효성분으로 포함하는 숙취해소용조성물 및 이를 이용한 기능성 건강식품
JP2007008883A (ja) 血糖値低下作用を有する組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase